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Abstract
Background: Nutritional treatment has always represented a major feature of CKD management. Over the decades,
the use of nutritional treatment in CKD patients has been marked by several goals. The first of these include the
attainment of metabolic and fluid control together with the prevention and correction of signs, symptoms and
complications of advanced CKD. The aim of this first stage is the prevention of malnutrition and a delay in the
commencement of dialysis. Subsequently, nutritional manipulations have also been applied in association with
other therapeutic interventions in an attempt to control several cardiovascular risk factors associated with CKD and
to improve the patient's overall outcome. Over time and in reference to multiple aims, the modalities of nutritional
treatment have been focused not only on protein intake but also on other nutrients.
Discussion: This paper describes the pathophysiological basis and rationale of nutritional treatment in CKD and
also provides a report on extensive experience in the field of renal diets in Italy, with special attention given to
approaches in clinical practice and management.
Summary: Italian nephrologists have a longstanding tradition in implementing low protein diets in the treatment
of CKD patients, with the principle objective of alleviating uremic symptoms, improving nutritional status and also a
possibility of slowing down the progression of CKD or delaying the start of dialysis. A renewed interest in this field
is based on the aim of implementing a wider nutritional therapy other than only reducing the protein intake,
paying careful attention to factors such as energy intake, the quality of proteins and phosphate and sodium intakes,
making today’s low-protein diet program much more ambitious than previous. The motivation was the reduction in
progression of renal insufficiency through reduction of proteinuria, a better control of blood pressure values and
also through correction of metabolic acidosis. One major goal of the flexible and innovative Italian approach to the
low-protein diet in CKD patients is the improvement of patient adherence, a crucial factor in the successful
implementation of a low-protein diet program.
Background
Historical background of low-protein diets for renal diseases
Dietary protein restriction is the mainstay of the nutri-
tional therapy for CKD. Since the 19th century it had
been realized that uremic syndrome derives from the
retention of molecules and toxins resulting from the
catabolism of exogenous proteins, usually excreted with
the urine. However, it was only in the 1960s, that Giovan-
netti and Maggiore suggested the low-protein diet as a
therapy for advanced CKD [1]. At that time dialysis was
still in the experimental stage and only a small number
of patients could benefit. A protein restricted diet pro-
viding adequate amounts of aminoacids and energy
supply was therefore the only widespread means to alle-
viate uremic symptoms and to prolong survival [1].
Thereafter, dialysis techniques and facilities, as well as
kidney transplantation, rapidly developed as replacement
therapies for ESRD. Although these therapies came to
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represent milestones in the history of modern medicine, at
the same time they reduced interest in the low-protein diet
as a treatment for advanced CKD. Nonetheless, with the
aid of the Brenner theory and its central aim of reducing
protein-related glomerular hyperfiltration and hypertrophy,
the low-protein diet was seen as a means to protect residual
renal function and to slow down the CKD progression to
ESRD [2]. Later, the availability of renoprotective and anti-
proteinuric drugs (RAS inhibitors) again limited the imple-
mentation of dietary intervention in CKD. However, the
low-protein diet still remains a viable means in the
prevention or treatment of several metabolic and clinical
abnormalities during CKD, as well as in the reduction of
proteinuria, either in association with RAS inhibitors or in
patients who cannot be treated with these drugs [3].
It is noteworthy that urea (as a marker of uremic
toxins) reduction is not the only aim of the low protein
diet. Indeed, in the early 1980s Maschio and Barsotti
highlighted the importance of protein restriction in the
reduction of phosphorus intake in moderate to advanced
CKD [4, 5]. This aspect, neglected for many years, now
enjoys significant renewed interest stimulated by the
evidence of the key role of phosphorus retention in the
pathogenesis of the so-called CKD-MBD and in the
progression of renal disease [6, 7].
Dietary sodium restriction is another aspect of the
nutritional therapy for CKD, as it allows better manage-
ment of sodium and water retention, blood pressure
control, and reduction of proteinuria [8].
Last but not least, it is of paramount importance to
underline that the renal diet is not only a matter of
restriction. It is also essential to ensure that the full
energy requirement is met in CKD patients (whether on
low-protein or following autonomous diets), in order to
prevent protein catabolism, maintain neutral nitrogen
balance, and to maintain adequate nutritional status and
body composition [9]. Contrary to just prescribing a
low-protein diet, a comprehensive nutritional approach
for CKD patients is to be considered mandatory.
An important improvement in the dietary treatment
for advanced CKD was the availability of protein-free
foods [10]. These products consist of carbohydrates
(starch) and are virtually free of nitrogen, potassium,
phosphorus and are also low in salt content. They eff-
ectively replace analogous staple foods (bread, pasta, bis-
cuits) making it possible to reduce the intake of protein
of low biological value, and thereby allowing adequate
intake of animal proteins whilst ensuring a high energy
intake. Such protein-free products have been widely
available in Italy for some time and, nowadays, can also
be obtained in other countries around the world. In the
early years, protein-free products were far less palatable
than corresponding foods, thus limiting patient adher-
ence. In the last few years, however, these foods were
further developed and their palatability much improved.
It is in fact notable that the risk of “malnutrition” associ-
ated with a low-protein diet is usually the result of an
insufficient energy intake rather than of a low protein
supply. Hence, when protein-free products are refused by
patients or are unavailable, a vegan diet can be offered as
an alternative, providing low protein (0.7/kg/dayay), low-
phosphorus and an adequate support of essential aminoa-
cids derived from a strict combination of cereals and
legumes [11]. At the same total protein content, the vegan
diet allows more favourable effects including a lesser net
acid production, a greater anti-proteinuric effect and a
lower net intestinal absorption of phosphorus [12]. The
observation that the vegan diet has effects similar to that
of a conventional low-protein diet also permits an alterna-
tion between the two, thereby increasing the choice of
foods and, consequently, the patients’ adherence [13].
Finally, when a modest restriction of protein and phos-
phorus is not enough (as in the case of severe reduction
of renal function), a very low-protein (0.3 g/kg/day), very
low-phosphorus diet supplemented with calcium, folates,
group B vitamins and mixtures of essential aminoacids
and ketoacids, can be prescribed [14, 15].
Though low-protein diets supply low amounts of pro-
teins they are high in carbohydrates, which are contrain-
dicated for patients with nephrotic syndrome or diabetes
mellitus. However, in the late 1980s the beneficial effects
of protein restriction on glucose metabolism [16–18],
and also proteinuria [19–22] were proven. Hence, the
change in the quantity and quality of dietary proteins is
indicated even in diabetic and proteinuric renal diseases.
In summary, protein restriction, including reduction of
phosphorus and salt, together with adequacy of energy
intake, represent the general characteristics of the nutri-
tional therapy for CKD patients. Moreover, the severity
of restrictions and the amount and quality of food and
supplements should be defined in accordance with the
advancement of CKD and the clinical conditions under
which it is observed.
Epidemiological data show that CKD is very common,
particularly in elderly patients with comorbidities, includ-
ing cardiovascular diseases, diabetes and hypertension. At
the present time, the CKD population is much older in
comparison to previous decades [23, 24], a factor that in-
troduces psychological and socio-economic elements that
must be dealt with. Thus, the nutritional management of
renal patients becomes more and more complicated and
far removed from a simple schematic dietary plan solely
related to the degree of renal impairment [14]. Nutritional
treatment must be increasingly focused and adapted to pa-
tient characteristics as well as to clinical and extra-clinical
needs. This is in order to obtain the maximum benefits
whilst minimizing the risks, as well as to achieve satisfac-
tory patient adherence to dietary prescriptions [25].
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Although the effect on lowering the GFR decline rate
seems small [26, 27], protein restriction appears capable
of reducing by 31 % the relative risk of initiating dialysis
[28]. In addition, in patients with ESRD, a low protein
regimen can also allow a reduction in the frequency of
dialysis [29–31]. Ultimately, these results are of great
interest to the patient, nephrologist and health care
system alike.
Discussion
Rationale and goals of nutritional treatment in chronic
renal insufficiency
Protein waste products in the pathophysiology of renal failure
With the aim of understanding the possible role of diet in
controlling uremic symptoms and reducing the rate of
progression towards end stage renal disease, one should
consider separately each dietary component. These are:
protein waste products, phosphate, sodium, and acid load.
Uremic syndrome is due to progressive reduction in
renal function, leading to impairment of several biochem-
ical and physiological functions. Impaired kidney function
reduces the excretion of many compounds that conse-
quently accumulate in extra- and intracellular compart-
ments and which contribute to the development of the
uremic syndrome. These uremic toxins mainly include
protein-bound substances and free water-soluble mole-
cules of low to medium molecular weight, [32–34], most
of which derive from protein breakdown [35]. Thus the
reduction of protein intake can reduce either the accumu-
lation of these toxins or the onset or severity of uremic
symptoms and complications.
Another possible source of aminoacid/protein derived
toxic compounds is the bacterial fermentation of proteins
in the intestine, leading to increased indoxyl sulfate and p-
cresyl sulfate serum levels [36, 37]. These toxins have been
associated with CKD progression and CKD-related compli-
cations, and could contribute to an acceleration in cardio-
vascular disease and uremic bone disease. The predictive
role of baseline indoxyl sulfate and p-cresyl sulfate levels
for CKD progression have been found to be significant,
even after adjusting for age, gender, diabetes status,
albumin levels, eGFR, calcium x phosphorous product,
PTH, hemoglobin, and high-sensitivity C-reactive pro-
tein [38]. Moreover, serum levels of indoxyl sulfate are
associated with overall and cardiovascular mortality
[39]. Reduced renal function determines the increase of
circulating uremic toxins, which may promote the CKD
progression (a self-reinforcing or vicious circle).
Phosphate in the pathophysiology of renal failure
Phosphate is mainly found in foods with high protein con-
tent, such as meat and cheese. The kidneys regulate serum
phosphate concentration by modulating its urinary excre-
tion and balancing the net phosphate absorption from the
gastrointestinal tract. In the past, concerns regarding the
consequences of phosphate retention in moderate to
advanced CKD were mainly focused on its negative effect
on bone mineralization. Excess of phosphate causes the
increase of FGF-23, inhibits the production of 1,25(OH)D3,
increases PTH, and alters polyamine metabolism [40]. In
previous years greater attention was paid to the cardiovas-
cular effect of impaired mineral metabolism and a com-
prehensive nomenclature, CKD-MBD, was given to this
complication [41]. It has been accepted that the major role
of phosphate retention on patient outcome is due to its
unfavorable effects on arterial and coronary calcification,
left ventricular mass, cardiac fibrosis and possibly CKD
progression [42, 43].
Sodium in the pathophysiology of renal failure
A reduced kidney function increases the body total
sodium pool and causes hypertension and edema; this is
in part due to reduction in GFR and in part to the
activation of the sympathetic nervous system and the
renin-angiotensin-aldosterone system. A high salt intake
increases the amount of urinary protein excretion [44,
45], a major risk factor for the onset and progression of
both kidney and cardiovascular disease. A double blind
study demonstrated that by reducing salt intake from 10
to 5 g/day urine protein excretion reduces by about
20 %. A subsequent double blind study showed that an
even smaller reduction in salt intake, from 9.7 to 6.5 g/
day, reduces urinary albumin excretion in people with
mild hypertension [46, 47].
Metabolic acidosis in the pathophysiology of renal failure
Acid excretion (mainly as phosphates and sulphates) and
the regeneration of bicarbonate both decrease with lower-
ing renal function, leading to metabolic acidosis that has
several negative consequences, including bone mineral
loss, muscle wasting, reduced protein anabolism and in-
creased protein catabolism. All these changes contribute
to protein malnutrition and progressive impairment of
nutritional status. Another significant effect of acidosis is
the shift of potassium from the intracellular to the intersti-
tial fluid, causing hyperkalemia, and hyperphosphatemia.
Finally, evidence exists that metabolic acidosis also con-
tributes to the progression of renal damage [48–50].
Protein and aminoacids metabolism in chronic renal
insufficiency
Humans are able to maintain lean body mass and body
protein balance over a broad range of dietary protein
intakes. Studies performed by whole body, steady-state,
stable isotope infusions have shown that the human
body responds to a reduced protein intake with inte-
grated and adaptive metabolic changes. These include a
reduction in aminoacid oxidation with more efficient use
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of aminoacids derived from protein degradation, a de-
crease in protein degradation and, ultimately, a decrease
in whole body protein synthesis [51, 52]. Impaired ability
to activate these adaptive mechanisms in patients with
renal function impairment would compromise nitrogen
preservation when nutrient/protein intake is reduced.
The understanding of how renal function impairment
affects the body’s ability to respond to changes in nutri-
ent intake is relevant since low-protein, high-calorie di-
ets are commonly used in conservative CKD treatment.
Nutritional impairments, such as malnutrition or cach-
exia, are more often clinically evident in advanced CKD
(stage 4–5) and even more at the beginning of renal re-
placement treatment. Mechanisms causing muscle protein
loss are complex and not always associated with anorexia,
but they are linked to several abnormalities that stimulate
protein degradation and/or decrease of protein synthesis
[53]. During the CKD course, the loss of kidney excretory
and metabolic functions is associated with the activation of
some pathways of endothelial damage, including in-
flammation, acidosis, resistance to anabolic hormones,
and defective insulin signalling [54]. These factors may
overlap those already operating in ageing and in co-
morbid conditions, such as diabetes, inflammation and
infections, favouring protein energy wasting [55, 56].
Recent advances in experimental uraemia have consistently
increased our understanding on intracellular pathways pro-
ducing loss of muscle mass. Metabolic acidosis increases
aminoacid oxidation and protein degradation through an
upregulation of the ATP-dependent, ubiquitin-requiring
pathway [53]. In addition, impaired signalling through the
insulin receptor substrate-1/phosphoinositide 3-kinase/
Akt pathway can predispose to catabolism through the
up-regulation of atrogin-related proteolytic pathways [57].
These effects may be especially injurious in uremia, where
impaired IGF-I signalling decreases the proliferation
of satellite cells and blunts muscle remodelling and
regeneration [58, 59].
Uremia-specific alterations in muscle aminoacid metab-
olism can also accelerate catabolic processes. Low levels of
ketoisocaproate, ketoisovalerate and ketomethylvalerate,
the respective ketoanalogs of leucine, valine and isoleu-
cine, all occur in plasma and in muscle cells of uremic
patients [60]. A reduced release of valine and leucine and
their ketoacids from muscle is responsible for their re-
duced blood levels [60]. These abnormalities arise largely
because of impaired dietary intake, urinary protein losses,
reduced renal metabolism and synthesis, and increased
BCAA catabolism in muscle [53].
Experimental evidence shows that, provided metabolic
acidosis is corrected and energy intake is adequate, pa-
tients with advanced stage CKD can fully adapt to low
protein regimens. Several nitrogen balance studies have
shown that patients with advanced CKD can maintain
neutral or slightly positive N balance with protein in-
takes as low as 0.55-0.6 g/Kg [52]. Indirect data suggest
that the mechanisms by which protein turnover adapts
to a low protein intake can be impaired in the presence
of metabolic acidosis [61]. Other studies indicate that
when acidosis is corrected, the adaptation of protein
metabolism to low protein diets is unimpaired. Indeed,
in non-acidotic patients with moderate renal impair-
ment the adaptive response to a standard low-protein
diet (0.6 g/kg/day) include a normal decline both in the
rates of whole body leucine oxidation and protein deg-
radation [62, 63].
Two studies indicate that protein metabolism and N
balance adapt successfully also in patients with uncompli-
cated CKD who are compliant to a VLPD supplemented
with essential aminoacids and ketoacids. Masud et al. ad-
ministered a VLPD (0.28 g/protein/kg) supplemented with
ketoacids or aminoacids in non-acidotic CKD patients
[64]. When patients were studied 3 weeks after the start of
VLPD regimen, they found that body nitrogen balance
was neutral and that this was achieved by a marked reduc-
tion in whole body aminoacid oxidation and postprandial
inhibition of protein degradation. In a second study, the
long-term adaptive response of six patients to a VLPD
supplemented diet was evaluated [9]. After more than one
year of very low protein diet, the rate of body N balance
was neutral and did not differ from basal values. In
addition, the whole protein synthesis, protein degradation
and leucine oxidation were similar to baseline. Also, in the
long-term, the neutral N balance was maintained by a
suppression of aminoacid oxidation and inhibition of pro-
tein degradation. As a whole, the evidence existing in the
literature shows that low-protein diets (up to 0.3 g
protein/kg) are nutritionally safe during advanced CKD
provided there is sufficient energy and aminoacid intake
and correction of metabolic acidosis.
Adaptation to low protein diets: energy metabolism in
chronic renal insufficiency
Energy metabolism in CKD is to some extent still un-
clear. Resting energy expenditure in stable patients with
chronic renal failure on conservative treatment does not
differ from control subjects [65]. However, patients with
advanced CKD may develop protein-energy wasting and
low dietary energy and nutrient intakes are often associ-
ated. It is possible that low energy intake represents an
adaptive response to reduced energy needs. Alterna-
tively, EE could be normal or high and a low energy in-
take would be inappropriate. Studies aimed at evaluating
EE measurement in renal patients in the resting state, as
well as during mild to vigorous exercise, confirm that no
difference exists when EE in patients with advanced
renal insufficiency is compared to that of normal sub-
jects. These findings suggest that for a given physical
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activity, energy expenditure in non-dialyzed, chronically
uremic patients should not be different from normal
[65]. Therefore, the low energy intake of many of these
patients may be inadequate for their needs, causing a
negative energy balance that in turn leads to protein-
energy wasting [66].
The association between dietary energy and protein me-
tabolism was evaluated in clinically stable, non-dialyzed
CKD patients fed with different dietary energy intakes (45,
35, 25 or 15 kcal/kg/day), at the same low protein intake
(0.55 to 0.60 g/kg/day [67]. Nitrogen balance correlated
directly with energy intake, and although some clinically
stable non-dialyzed chronic uremic patients ingesting 0.55
to 0.60 g protein/kg/day may maintain a neutral nitrogen
balance with an energy intake below 30 kcal/kg/day, a
dietary intake providing approximately 35 kcal/kg/day is
more likely to maintain neutral or positive nitrogen bal-
ance, maintain or increase body mass, and reduce net urea
generation. Thus, a crucial aspect of nutrient intake in
CKD is the amount of energy supply. Essentially, in the
presence of a reduced protein intake, a neutral or positive
nitrogen balance requires high energy intake, whereas a
low energy intake causes protein degradation, negative
nitrogen balance and loss of lean body mass.
There is evidence that many patients with CKD spon-
taneously reduce their energy intake as GFR decreases
[68]. The failure to maintain adequate energy intake may
be due to several factors including: anorexia, nausea,
fatigue, anemia, restrictive therapeutic diets, co-morbid
diseases and psychosocial factors. The age of CKD
patients makes the energy intake pivotal in maintaining
an acceptable nutritional status. Indeed, being elderly
induces a worsening in dietary habits because of several
factors, such as depression, anorexia, delayed gastric
emptying, altered gastric distension, hormonal changes,
taste and smell deterioration, pill burden and insulin
resistance. Consequently, elderly patients with advanced
renal insufficiency are at very high risk of protein energy
wasting. Besides age, also of relevance in the prescription
of energy intake is the strict relation between EE, gender
and physical activity of which must also be taken in
consideration. Indeed, daily EE is lower by 8-14 % and
16-20 % in sedentary adult women and men respectively.
In addition, elderly people show a decline in resting EE
(linked to a 3 % loss of lean body mass per decade) [69].
Based on this evidence, the most recent dietary reference
intakes (Food & Nutrition board) provide the mean indi-
vidual energy requirement for a 30-year old adult, from
which the requirements for older women and men can
be calculated by reducing the value for 30-year olds by 7
and 10 kcal per additional year of age, respectively [70].
Finally, there is a metabolic adaptation to reduced
energy intake, which includes a decrease in resting EE
due to the loss of lean body mass and to an improved
efficiency of energy metabolism. Thus, when the energy
intake does not reach the recommended values, mal-
nourished CKD patients benefit from any increase in
their nutritional intake, mainly a high energy supply.
As to the role of LPD, it has been shown that LPD
ncreases insulin-mediated glucose disposal in CKD
[71]. LPD ameliorates insulin sensitivity in renal insuf-
ficiency, even for low plasma insulin concentrations.
The causative role of LPD-induced metabolic changes
is not yet well known. Nonetheless, since the rate of
energy production is increased by LPD, the energy
intake should be increased when protein intake is
restricted.
In summary, full compliance with patient energy re-
quirement is mandatory for correct adaptation of protein
metabolism to dietary protein restriction. The recom-
mended daily energy intake in CKD should be 35 kcal/kg/
day for patients aged < 60 years; and 30 kcal/kg/day for
those aged > 60 years. These recommendations for energy
intake must be adapted to the individual patient’s needs,
and will mostly depend on the level of physical activity.
Strategies for different low-protein diets for CKD in
Italy (Table 1)
Normal-protein, normal-sodium diet
In healthy adults the RDA for proteins has been set at
0.8 g/kg/day, which meets metabolic requirements in
97.5 % of the adult population [72]. Recommendations on
dietary salt intake for the general population have also
been recently issued, mainly on the basis of cardiovascular
effects associated with different levels of salt intake [73].
Generally, the recommendation is for a reduction in so-
dium intake to < 100 mmoL/d (i.e., < 5.8 g/day sodium
chloride). Since preliminary evidence seems to indicate
that severe reductions (<6 g/day) may not be safe
[74], optimal dietary salt should be 4–6 g/day. There-
fore, a “normal” diet for healthy adults in the general
population should contain 0.8 g/kg/day proteins and
nearly 6 g/day of salt.
Practical fulfilment of these recommendations does how-
ever prove to be far from theory. Typical PI in developed
countries are as much as 3.0 g/kg/day [75]. In Italy, a small
study showed a mean PI of 1.3 ± 0.6 g/kg/day, with 73 %
and 26 % of subjects evidencing levels higher than 0.8 and
1.6 g/kg/day, respectively [76]. The picture for sodium
intake is even worse. Indeed, analysis of surveys on sodium
intake from 66 countries throughout the world has revealed
that the estimated mean level of sodium consumption in
2010 was almost double the RDA value and accounted for
nearly 10 % of deaths [77]. In the Italian adult population,
average salt intake is 10.9 g/day in men and 8.5 g/day
in women, with intakes > 5 g/day in 97 % and 87 %,
respectively [78].
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This complex scenario has led the new guidelines on
CKD management to suggest an appropriate nutritional
education program aimed at achieving a protein intake
of 0.8 g/kg/day in all adults with GFR less than 30 ml/
min/1.73 m2, whilst also avoiding a high protein intake
(>1.3 g/kg/day) in all patients at risk of CKD progression
[79]. Recommendations for CKD patients with higher
GFR and/or at low risk of CKD progression remain un-
defined. When considering that most CKD patients have
salt-sensitive hypertension [80], the only recommenda-
tion is a lowering of salt intake to 4–6 g/day, unless
contraindicated (i.e. salt losers, volume depletion) [79].
However, guidelines are essentially based on findings
from randomized trials, and “optimal” testing of the effi-
cacy of nutritional interventions is difficult not only due
to economic restrictions (limited or any funding for
RCT on non-pharmacologic interventions) but also to
problems inherent to the study (such as poor adherence
to diet that ultimately affect results). With such ambigu-
ity in efficacy it may be wise to resort to pathophysi-
ology, which has demonstrated the importance of
adapting dietary intakes to impaired renal function
[81], and to “pragmatically” pursue in CKD the dietary
goals established for the general population. Therefore,
prescribing a “normal” diet should be the basic ap-
proach in most CKD patients. It is noteworthy that in
patients with CKD and eGFR < 60 ml/min*1.73 m2, only
one out of two complies with the 0.8 g/kg/day protein
regimen and one out of five adheres to the 6 g/day
dietary salt prescription despite regular nephrology care
[82, 83].
Nevertheless, these findings should not prevent efforts
in dietary intervention among nephrologists. Indeed, even
small reductions in protein intake, such as a decrease of
0.2 g/kg/day versus usual diet, still allows significant
improvements in metabolic profile and in the risk of
renal death [3, 28]. Similarly, CKD patients under renin-
angiotensin system inhibitors show better renal prognosis
when adhering to salt restriction even if of moderate
degree (7 to 10 g/day versus >12-14 g/day) [84, 85]. This
holds true mainly because salt restriction potentiates the
anti-proteinuric efficacy of RAS inhibitors [86].
Overall, these data and the certainty that effectiveness
of nutritional therapy is impaired if most patients are
not adherent, should stimulate nephrologists into pre-
scribing the “normal” diet to all their CKD patients as the
first approach, being aware that even small decreases in
the protein-salt consumption are beneficial. Adherence to
“normal” diet may guide future decisions on switching the
patient to a more restricted, and potentially more effective,
dietary regimen.
A “normal diet”, aiming at intakes of 0.8 g/kg/day of
protein, normal energy intake, and 100 mmol/day of salt,
can be easily prescribed to all CKD patients with the
suggestion of avoiding “excessive” intakes of proteins
[87]. Patient attention should also be drawn to the im-
portance of healthy diets, namely a “Mediterranean” or
“DASH” diet.
Conventional low-protein, low-phosphorus diet
The progressive loss of renal function during the course
of CKD leads to defective excretion capacity of several
waste products and minerals which accumulate in the
body. When renal function in impaired, the renal handling
of nutrient waste products and electrolytes is various. For
instance, urea and organic acids accumulate as the GFR
declines. In contrast, for other solutes such as phosphate
and sodium, a body neutral balance is maintained (till
advanced or even very advanced renal function decline)
thanks to the activation of some pathophysiological, adap-
tive mechanisms that, however, are detrimental (“trade-off
hypothesis”) for the kidney and the whole body (i.e.
Table 1 Dietary composition of low-protein diets for CKD patients
Normal diet LPD Vegan VLPD
Nutrients
Energy requirement normal high high high
Protein, g/Kg/d 0.8 0.6 0.7 0.3-0.4
Prevalent origin of proteins Mixed Animal Plant Plant
Phosphate, mg/d 700-800 500-600 500-600 300-400
Sodium, mmol/d 100 100 100 100
Supplements
Free-protein products use Optional Yes No Yes
EAA + KA No Optional Optional Yes
Calcium, g/d Optional 0.5-1.0 0.5-1.0 0.5-1.0
B12 Vitamin No Optional Yes Yes
Iron No Optional Yes Yes
EAA essential aminoacids, KA ketoacids
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FGF-23 increase, secondary hyper-parathyroidism; extra-
cellular volume expansion and consequent heart failure
and arterial hypertension).
Major metabolic derangements in CKD occur from
stage 3b. Most patients show overt secondary hyper-
parathyroidism, increased potassium and phosphate serum
levels, metabolic acidosis, anemia and sub-clinical water
retention [88, 89]. In this phase of renal disease a basic
renal diet (low-normal protein diet; see above) is no longer
capable of neutralizing the increased retention of nutrient
waste products and related clinical complications. Thus, in
CKD 3b it is conceivable that a more restricted nutritional
treatment can be started, with the purpose of reducing the
load of those products which have impaired renal handling
and thereby improving uremic signs and symptoms, uremic
toxicity, preventing the onset of malnutrition, and, possibly,
preventing or reducing the CV risk factors whilst also
delaying the start of renal replacement treatment [14].
A “conventional low-protein diet” for adult patients
with established CKD should contain: 0.6-0.7 g/kg/day
of protein (>50 % at high biological value such as meat,
fish and egg). To avoid a negative nitrogen balance with
such a reduced protein intake, the energy intake should
be in the normal-high range, that is, 30–35 kcal/kg/day,
derived from lipids (around 35 % of the total amount
preferably from vegetarian origin, with cholesterol less
than 300 mg/day and saturated fat less than 5 %) and
carbohydrates (around 55 %). This “diet” is also low in
phosphate (600–800 mg/day), sodium (2–3 g/day), or-
ganic acids, potassium and calcium content and may,
therefore, be supplemented with calcium (400–800 mg
elemental calcium per day). To accomplish the goals of
low protein, normal-high energy intake and balanced
intakes of macronutrients at one and the same time,
such a “conventional low-protein diet” requires the use
of protein-free products for the main source of energy.
Today these products are usually available as pasta,
bread and flour but also as precooked soups and desserts
and represent a very valuable resource for optimal low-
protein dietary management of CKD, allowing high en-
ergy intake with no phosphate, absence of protein of low
biological value, and a lower sodium burden.
The main role of a “conventional low-protein diet” in
the moderate to advanced stages of CKD is based on its
effect on the metabolic abnormalities of CKD. Even a
slight reduction of protein intake of 0.2 g/kg/day achieves
significant metabolic improvements on uremic state,
metabolic acidosis and hyperphosphatemia [3]. Indeed,
the protein prescription of 0.6 g/kg/day compared with a
0.8 g/kg/day protein diet allows a better control of hyper-
parathyroidism and metabolic acidosis, even if adherence
to the diet is incomplete [90]. Also, a robust interaction
has been demonstrated between nutrition and cardio-
renal protection. In fact, in non-diabetic CKD patients
receiving ACEi, the reduction of salt intake (to 6 g/day)
enhances the urinary protein-lowering effect of ACEi,
either alone or in dual angiotensin block [85]. Moreover,
in patients from the REIN study, the urinary protein-
lowering effect of ACEi declines as serum phosphorus
increases, suggesting that phosphorus impacts the reno-
protective effect of ACEi [7]. Hence, in CKD comprehen-
sive nutritional treatment reduces uremic signs and
symptoms and also allows a lessening of the CV risk.
Major concerns for this dietary regimen are adherence
and safety. Patient compliance to a low-protein diet is
low. Since major determinants of adherence are under-
standing (knowledge) and satisfaction of the patient
(achieving their objective, receiving required support)
[91], to pursue this aim requires skilled dietitians, indi-
vidualized dietary programs, intensive educational pro-
grams and regular counselling [92], all of which require
dedicated personnel and extra resources of time and
funding [93] and are rarely available in common clinical
practice [94]. An option for overcoming this limitation is
found in simplified approaches to “conventional low-
protein diet” which may be practiced when dietitians are
not available [87, 95].
As for nutritional safety, given an adequate energy
intake (i.e. in the normal-high range, 30–35 kcal/kg/
day) and correct nutritional monitoring, it has been de-
finitively demonstrated that malnutrition is extremely
rare in CKD patients on a low-protein diet. In a ran-
domized trial in which more than 400 CKD patients on
a low-protein diet were followed for 30 months, only
three subjects developed malnutrition (less than 1 %)
[96]. Overall, the side effects of a “conventional low-
protein diet” in CKD are negligible and can be easily
prevented with careful, standard clinical monitoring
(see above).
Vegan low-protein, low-phosphorus diet
As specified above, a conventional low-protein diet re-
quires the use of protein-free products as the main energy
source. Unfortunately in some circumstances these ar-
tificial foods may have poor palatability and be expensive
and psychologically unacceptable to the patient, especially
when consumed away from home . When the intake of
protein-free products is inadequate, the unwanted conse-
quence is low energy intake leading to loss of fat and lean
body mass.
To overcome the need of protein-free foods, we im-
plemented a vegetable-based, low-protein (0.7 g/kg body
weight/day), high energy (30 to 35 kcal/kg/day) vegan
diet. The major limitation of a vegetarian low-protein
diet is the adequacy of essential aminoacid supply, since
plant proteins are not considered as high biological-
value proteins. This diet used a cereal-legume combin-
ation to meet the essential aminoacid requirement [11].
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Such a combination may appear at first sight to be inad-
equate, as it is well known cereals are low-biological
value proteins because they are poor in lysine content;
and legumes are lacking in methionine. However, ce-
reals are rich in methionine whereas legumes are rich in
lysine, making these foods complementary in aminoacids
composition. A precise combination of each, therefore, is
fully capable of providing the essential aminoacids
requirement.
Notably, at the same protein intake, plant origin pro-
teins have a lower impact on glomerular permeability
and hemodynamics than animal protein [97], and the
net acid production is lower. A vegan diet has a favor-
able lipids and fatty acids composition and also contrib-
utes to the lowering blood pressure. Phosphate is mostly
present as phytate, with a quite lower intestinal absorp-
tion rate, so reducing, even at equal phosphate content,
the actual dietary phosphate load [12]. Of note, in
this diet, meat or fish are not allowed, making iron
and vitamin B12 supplements necessary.
The limitation of food choices in the vegan diet, as
well as in the conventional low-protein diet, may prove
too unimaginative and repetitive in the long-term and
as such represents the main factor limiting patient
adherence. Since the vegan diet achieved comparable
results to the conventional low-protein diet, one sugges-
tion is to alternate these two diet regimens. This strat-
egy avoids the exclusion of a food category (namely
cereals during conventional low-protein diet, or animal
proteins during vegan diet), and reduces the need of
protein-free foods [13]. On the whole, alternating vegan
and conventional low-protein diets was well accepted by
patients and it may represent a further practical alterna-
tive for many patients on long-term dietary protein
restriction.
Very low-protein, very low-phosphorus supplemented diet
The VLPD is a vegetarian diet that includes protein-free
artificial foods, vegetables, fruits and supplementation of
essential aminoacids (EAA) and ketoacids [11]. The
VLPD composition for an adult man of 70 kg body
weight ensures 2100–2500 kcal, 21 g of proteins, 73-
80 g of lipids (4 % saturated), 310-350 g of carbohydrates
(12 % simple carbohydrates), 16 g of fibers, 30–40 mmol
of sodium, 35–50 mmol of potassium, 350-450 mg of
phosphate, 3-5 mg of iron and 200-250 mg of calcium.
Supplements are administered as tablets containing L-
lysine (105 mg), L-threonine (53 mg), L-histidine (38 mg),
L-tyrosine (30 mg), hydroxy-methionine (59 mg), calcium-
keto-valine (86 mg), calcium-keto-phenylalanine (68 mg),
calcium-keto-leucine (101 mg), calcium-keto-isoleucine
(101 mg). This formulation is the Alfa-Kappa® used in Italy,
whereas globally Ketosteril® is used. The latter differs from
the former by the presence of Tryptophan. In order to
maintain a neutral nitrogen balance even at a very-low pro-
tein intake, tablets are given at the dose of 1 pill every 5 kg/
bw [98]. Use of supplements allows nitrogen recycling as a
means of building the essential aminoacids from the
relative ketoacids, thus further reducing serum urea levels.
Calcium content is 45 mg per tablet and the total calcium
intake is about 630 mg in an adult man of 70 kg (75-
80 % of RDA). Total nitrogen content is 37 mg. Due to
the very low nitrogen intake, a high energy intake (never
lower than 30–35 kcal/kg/day) is mandatory. Protein-
free foods allow an energy supply of 30–35 kcal/kg of
body weight with a low phosphate intake. Salty food,
food with additives, game, giblets, chocolate, puddings,
creams, sweets, liquors, dried and syrup fruit, bananas,
figs, tangerines, pomegranates, olives, mushrooms, spin-
ach and truffle are not allowed. Still water is suggested,
while a half glass of red wine is permitted at lunch and
dinner. A free-choice meal is allowed only once a week.
Patients may also dine out, but they are required to ask
the chef to refrain from adding salt, and are also ex-
pected to avoid sauces (such as ketchup, mustard, and
mayonnaise), and to request that dishes are cooked in a
simple way (grilled, roasted or boiled). To improve
the taste of food it is permissible to use vinaigrette,
celery, basil, parsley, marjoram, oregano, salvia, rosemary,
garlic and onion.
VLPD showed several additional positive effects. There
were lower indoxyl sulphate levels compared to usual
LPD [99]; a decreased need for erythropoietin [100];
better control of blood pressure, possibly through a
reduced salt intake [101]; lower urinary and plasma
phosphate and FGF23 levels [102]; and lower proteinuria
and better antiproteinuric response in patients assuming
ACEi and sartans [103]. Moreover, vegetables and fruits
increase plasma bicarbonate levels, thus improving the
metabolic acidosis [104]. Interestingly, vegan-vegetarian
supplemented LPD in pregnant women with CKD stages
3–5 reduced the risk of low gestational age babies and
may counterbalance the worsening of proteinuria and
kidney function associated with pregnancy related hyper-
filtration [105]. Also, in diabetic patients vegan supple-
mented LPD facilitated better management of CKD
progression whilst awaiting a combined pancreas-kidney
transplant [106]. Overall, the supplemented VLPD has
been demonstrated as safe during either the pre-dialysis
CKD period or during the following long-term dialysis
period for patients who previously received such a diet
[107].
The VLPD has recently received a final consensus
from experts in this field [14]. Obviously, VLPD manage-
ment requires significant expertise by nephrologists,
together with high patient compliance and acceptance of
lifestyle changes, social and family support and, above
all, a high doctor-patient empathy.
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Pragmatic personalized low-protein dietary approaches
The input for re-designing moderately restricted, simpli-
fied low-protein diets (to only later switch to a severely
restricted simplified low-protein diet) for CKD patients,
came from either clinical factors (difficulty in attaining
good dietary compliance) or resource-related issues (lack
of dedicated dietitian).
The tenets forming the basis of the simplified diets were
the following: to improve compliance, the diet should be
qualitative and not quantitative (nothing needs to be
weighed); the control of quantity of calories, protein,
sodium and phosphate content is based upon clinical
assessment, body weight control, diet diary, serum and
24 h urine parameter levels. One to three unrestricted
meals per week are allowed, to ease the psychological
burden of dietary restrictions and as a tool to limit the risk
of under-nutrition. Indeed, the example of the Okinawa
diet suggests that occasional intake of particular nutrients
may be favourable, thus overcoming the concept of daily
needs [108]. The choice of the type of diet depends upon
the patient’s preferences. A moderately restricted diet may
be the first step towards a further reduction (i.e. a very
low-protein diet), which combines a vegan approach and
protein-free commercial food. The addition of the com-
bined ketoacids and aminoacids supplements allows for
erring “on the safe side” as regards integration of different
plant-derived proteins, thus permitting a purely qualitative
approach in relation to forbidden and allowed food. Such
a qualitative approach is also used for diets based upon
the substitution of pasta and bread with protein-free food.
Other diets, whether vegan, traditional or tailor-made
require a qualitative and quantitative approach.
Starting from situations in which conventional low-
protein diets were rarely employed, such as with type 1 dia-
betic patients and pregnant patients [106, 109], a multiple
choice, stepwise treatment approach has been developed.
While diet composition is discussed elsewhere in detail
[87], four major points may summarize this approach [110,
111]. The strategy is centred on the low-protein diets
considered on the whole as an integrated menu in which
patients should chose the “diet” which best suited their
preferences, according to the following suggestions: 1)
chose the diet you prefer (or that which bothers you least);
2) change it if you want to try a different approach; 3) do
not weigh food (qualitative approach); 4) enjoy 1–3 unre-
stricted meals per week. To facilitate the shift among differ-
ent diets, these are built with a common frame plus a
variable part which satisfies the different protein targets
(0.6 with protein-free food; 0.6 vegan supplemented; 0.6-
0.8 vegan non supplemented; 0.3 vegan with protein-free
products supplemented with essential amino acid and
ketoacids). Patients chose different diets when these op-
tions of protein restriction were offered. In agreement
with experience gathered from other vegan diets and with
alternation of vegan diets, and of diets using commercial
protein-free food, this approach provides for good compli-
ance (protein intake aimed at 0.6 g/kg/day of proteins;
estimated as 0.5-0.7 g/kg/day), possibly because the mul-
tiple choice and the variety of different diets empowers
the patients [11, 13, 105, 111]. In a recent report on over
800 patient-years of observation where such a multiple
choice, stepwise dietary approach was applied, about 50 %
of the patients were still on follow-up after the first finding
of eGFR below 15 mL/min, previously considered as the
marker of “early” dialysis initiation, and about 25 % were
still on the diet for four or more years (50 % at 1 and 25 %
at 2 years considering eGFR below 10 mL/min) [112].
Dietary approach in special groups of CKD patients
Diabetes
Diet and lifestyle modifications are key components of
DM care and an optimal nutritional approach helps the
management of blood glucose, lipids, body weight and
blood pressure, thus reducing both the incidence and
progression of DM complications, including CKD.
The Italian Guidelines for DM Care suggest that people
at high risk of diabetes should be encouraged to follow a
diet rich in fiber from vegetables, fruits and whole grains
and low in animal fats. The first step in managing a diet
for a DM patient in an early stage of CKD is to ensure that
carbohydrate intake is within the recommended range of
45 %-60 % of total calories and the actual fiber intake is
similar to that of the general population (14 g/1000 kcal/
day) [113]. Dietary sodium and protein restriction should
be a mainstay in the nutrition therapy of all patients
with proteinuria and it has proven effective even in
overt diabetic nephropathy [85, 114–116]. When CKD
progresses, a high protein intake is detrimental for the
progressive decline of renal function. Indeed, the Italian
DM Standard Care [113], and the Canadian Diabetes
Association guidelines [117], recommend a LPD in the
clinical management of DM patients with CKD al-
though the benefits of protein-restricted diets have long
been debated [118, 119].
A recent Italian study in 74 older adults with T2DM
and CKD stages 3b-4 demonstrated the feasibility and
the adherence to a moderate protein diet (0,7 g/kg/day
for only 6 days/week); LPD regimen significantly re-
duced renal failure by 42 % [116]. This beneficial effect
is also associated with an improvement in low-grade in-
flammation, oxidative stress, and proteinuria, without
worsening glycemic control or nutritional status, dem-
onstrating its sustainability in the long term [116]. The
Italian clinical experiences started in the 1980s with the
use of a VLPD, low phosphorus and supplemented
diet, and involved both type 1 and type 2 DM pa-
tients [16, 120]. It was reported that a VLPD (protein
0.3 g/kg/day; phosphorus 5 mg/kg/day), supplemented
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with essential aminoacids and ketoacids, reduced the
decline of creatinine clearance in eight self-controlled
T1DM patients with renal failure due to overt dia-
betic nephropathy [16]. Later, in 22 T1DM and 10
T2DM patients, a beneficial effect on the progression
rate of renal failure and proteinuria was proven for a
protein restricted diet mostly consisting of foods of
vegetable origin, [120]. The Authors tested two differ-
ent patterns of diet (scheme A: 0.3 g protein/kg/day;
phosphorus 5.5-6 mg/kg/day; scheme B: 0.7 g protein/
kg/day; phosphorus 8.5-10 mg/kg/day). The B diet was a
pure vegetarian diet with complementary proteins (from
cereals and legumes) which meets completely the recom-
mended daily intake of essential aminoacids. The Authors
suggest that a moderately low protein vegetarian diet, such
as diet B, might represent the first choice in the early
stages of CKD due to diabetic nephropathy, while diet A
is to be preferred in patients with a GFR <20 mL/min for
delaying dialysis initiation. Overall, a recent meta-analysis
on 13 RCT and 779 patients affected by diabetes mellitus
indicates that the low-protein diet in such patients is
significantly associated with improvement of diabetic
nephropathy and moreover, is safe [115].
In conclusion, the dietary management of diabetic
patients with CKD includes limitation of sodium intake
to 1,5-2 g/day; an amount of carbohydrates equal to 45-
60 % of total energy supply; reduction of saturated and
trans fatty acids; with a fibre intake of 14-25 g/day being
highly recommended. Daily protein intake should be
approximately 0.8 g/kg/day in CKD stages 1–2 (lower
normal intake) and reduced to 0.7- 0.6 g/kg/day in CKD
stages 3–4; phosphorus content should be reduced
to < 800-1000 mg/day. In selected CKD patients with
CKD stage 5 and who were not in dialysis, a VLPD
diet supplemented with aminoacids and ketoacids
under strict clinical and nutritional follow-up, is a
viable option.
Nephrotic syndrome
Edema is a major clinical manifestation of the nephrotic
syndrome, due to extracellular fluid expansion secondary
to sodium and water retention. For this reason dietary
sodium restriction (2 to 3 g/day) should be recom-
mended. In the DASH diet the limitation of red meat
consumption is a strategy for reducing not only total
and saturated fat intakes but also sodium intake, espe-
cially from processed meats [121]. Moreover, the DASH
diet emphasizes increased consumption of protein from
vegetables, poultry and fish wherein the quantity of
sodium is lower [122].
In nephrotic syndrome, dietary intervention should
also include a modified quantity and quality of pro-
tein intake through LPD. In some experimental
models, LPD showed effective in decreasing the
urinary protein excretion [123, 124], and this effect of
LPD is synergic with ARBs agonist effects [125].
Human clinical trials proposed the LPD in proteinuric
patients due to its effect on albumin homeostasis.
Indeed, it was shown that in nephrotic patients the
LPD results in decreased urinary albumin excretion in
excess of any reduction in creatinine clearance and
increase in plasma albumin mass [19]. In nephrotic
syndrome, a reduced protein intake is also beneficial
because of the increased synthesis of albumin, reduced
proteolysis and the resulting increase in serum albumin
levels [126, 127].
As well as in the experimental studies, the contempor-
ary use of ACEi and LPD seems to have an additive
beneficial effect on proteinuria. Indeed, LPD induces
afferent arteriole vasoconstriction whilst ACEi induce
post-glomerular vasodilatation [128]. Also, sodium re-
striction has an anti-proteinuric effect, either alone by
itself or additive to that of ACEi and ARBs. To be sure,
sodium restriction plus an inhibitor of RAS equalled (or
even overcame) the effect of a dual blockade of renin-
angiotensin-system on proteinuria, at the same time also
limiting the risk of hyperkalemia. The reduction in
proteinuria due to both sodium and protein restriction
occurs to the same degree also in CKD diabetic patients
and seems to be independent from changes in blood
pressure [129, 130]. Also the VLPD supplemented with
ketoacids is effective in reducing nephrotic proteinuria;
the saving in terms of reduced protein excretion results
in a delay of commencement of dialysis independent of
the use of ACEi or ARBs [131, 132].
A vegan low-protein (0.7 g/kg/day), low-sodium diet
for nephrotic patients even with preserved renal func-
tion, has also been proposed [20]. This diet was supple-
mented with essential aminoacids and ketoacids to
partially cover the protein losses, so protecting against
nutritional impairment. Urine protein losses decreased
as well as LDL cholesterol levels, without detrimental
effect on serum albumin. Finally, a non-supplemented
vegan diet using soy as main protein source, exerted
similar favourable anti-proteinuric and lipid-lowering
effects [22].
Therefore, in proteinuric patients with normal or im-
paired renal function, it is reasonable to suggest diverse
low-protein diets, integrating the urine protein losses
and monitoring the nutritional status. In addition, the
use of ACEi and LPD together seems to have an add-on
beneficial effect on proteinuria, but with different mech-
anisms [128, 132].
In conclusion, sodium restriction represents the corner-
stone of dietary approach in nephrotic patients, and
changes in quality and quantity of dietary proteins may be
an additional, effective intervention associated with the
use of ACEi and/or ARBs.
Bellizzi et al. BMC Nephrology  (2016) 17:77 Page 10 of 17
ESRD: mixed dietary-dialysis approach
Giovannetti et al. and Locatelli et al. tested ESRD pa-
tients for a combination of dietary treatment plus a
once-weekly hemodialysis schedule [29, 30]. The ration-
ale was to ensure adequate metabolic control by com-
bining a toxin load reduction “upstream” with a “valley”
purification [133], while preserving as much as possible
the residual renal function through avoiding relevant
ultrafiltration rates during the dialysis session. This strat-
egy can be considered as a forerunner of an “incremen-
tal” dialysis program.
The integrated Dialysis-Diet program consisted in a
very low-protein diet, 0.3-0.4 g/kg/day, supplemented
with essential aminoacids and ketoacids for 6 days a
week, severe sodium and water restriction, and a once-
a-week hemodialysis session [29, 30]. The program
included patients with very-low residual renal function,
below 5 ml/min. An unrestricted protein intake was
permitted and mandatory on the day of dialysis treat-
ment. This free-diet day had positive effects also on the
psychological status of the patient. Despite a number of
favorable clinical, psychological and economic effects,
however, some concerns arose about patient compliance
and nutritional status [134].
Learning from these experiences and in order to
improve patient adherence, Caria et al. proposed a new
combined Diet-Dialysis program [31]. Included in this
program were patients with a higher residual renal func-
tion and the diet provided a less severe protein (0.6 g/
kg/day) and phosphorus restriction on the non-dialysis
days, but always respecting a high energy intake. A
protein-free diet on the day of the dialysis session con-
tinued to be considered mandatory also in this program,
in order to meet the increased nitrogen demand due to
the losses of aminoacids during the dialysis session.
When compared to a group of patients commencing at
once a thrice-a-week hemodialysis schedule, patients on
the combined Diet-Dialysis program showed a better
preservation of both residual renal function and urine
volume output, lower levels of β2-microglobulin, and
better phosphate control. The use of erythropoietin
stimulating agents, cinacalcet and non-calcium-non-
aluminum phosphate binders were all significantly
reduced in the experimental combined program. The
hospitalization rate was also reduced. Half of the
patients were still on Diet-Dialysis after 16 months [31].
An extension study showed a higher survival in patients
who started such combined treatment as compared to
those who commenced a regular thrice-a-week dialysis
schedule.
The combined Diet-Dialysis approach could be con-
sidered a bridge therapy towards a more frequent
hemodialysis, suited to selected and motivated patients.
Under these controlled conditions, it can increase patient
quality of life, prevent the rapid loss of either residual
renal function or urine output volume and, moreover,
it is cost-saving.
Nutritional care management
Surveillance during low-protein diets in CKD
Two main issues set the stage for a successful LPD:
prevention of protein-energy wasting and surveillance of
adherence to dietary prescriptions. For this reason, pa-
tients on LPD require frequent monitoring by skilled
personnel (nephrologists and dietitians). Nutritional
monitoring should be based on an integrated evalu-
ation approach, aimed at early diagnosis of PEW and
identification of risk factors, in order to prevent any
further depletion of protein and energy stores. Compli-
ance evaluation requires active patient involvement and
motivation. Literature data suggest that thoroughly moni-
tored LPD in compliant patients, combined with adequate
energy intake, are likely to be preventive rather than
causative of PEW [64, 135–139].
In this clinical condition nutritional assessment
should identify, characterize and stratify malnutrition,
as well as monitor the response to therapy. However,
early diagnosis of PEW risk is the key issue. No nutri-
tional parameter taken individually can accomplish all
these needs in renal patients. Currently, the available
bedside methods, though not expensive, are not accur-
ate and reproducible enough for the quantitative as-
sessment of nutritional status. Moreover, they are quite
often influenced by non-nutritional factors [140–147].
Nevertheless, changes over time in selected parameters
may represent an important element of diagnostic
utility.
A recent consensus published by the International
Society of Renal Nutrition and Metabolism has sug-
gested an integrated algorithm for regular (every three
months) nutritional monitoring in CKD patients [148].
Screening includes 4 categories of readily utilizable
criteria for the monitoring of nutritional status and clin-
ical diagnosis of PEW: biochemical parameters, body
mass, muscle mass and dietary intake (Table 2) [140]. A
fifth additional category that includes nutritional scoring
systems can be used as a complementary monitoring
tool of nutritional status. PEW is considered to be
present when at least one criterion in three out of four
categories is present [140]. Not all of these nutritional
variables have been introduced in daily clinical practice.
Even though each of them has specific limitations, the
most commonly used are represented by serum body
mass index, weight change, serum albumin levels, and
protein intake evaluation, since they are simple, nonin-
vasive, widely available and inexpensive [140]. Nutri-
tional scoring systems such as the Subjective Global
Assessment (SGA) of nutritional status or the Malnutrition
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Inflammation Score (MIS) are widely used in the nephrol-
ogy care setting because they integrate dietary history,
careful physical examination, and nutritional evaluation
[140].
A regular and careful evaluation of energy intake is
mandatory. In this regard, dietary history assessment by
a skilled renal dietitian is critical. The application of
periodic surveys and food diaries allows early interven-
tion, i.e., when the intake of calories is reduced but
nutritional status assessment has not yet detected any
alteration in nutritional variables [140]. Also, an early
detection of loss of appetite or anorexia may represent
the first index of a high risk condition for PEW. Protein
intake in clinically and metabolically stable patients (i.e.
in absence of acute comorbidities, such as infection and
surgery) can be derived from the calculation of protein
catabolic rate (PCR), based on a protein nitrogen ap-
pearance calculation by 24-h urinary nitrogen excretion
and body weight value [149].
In parallel to regular nutritional status monitoring
and dietary intake evaluation, patient motivation is to
be reinforced, as is the case for other chronic diseases
[150]. This can be attained by promoting active involve-
ment of patients and their families, taking into account
the different cultural and community issues. Namely,
food and supplement access, economic and religious
issues, health literacy etc. [151, 152]. In this regard, it is
likely that an interactive approach based on simple tools
describing permitted nutrients and the risk associated
with some categories of food and its additives/preser-
vatives, as well as the possibility of a more varied diet
could significantly improve motivation and dietary
adherence of CKD patients [153, 154].
Awareness and new comprehensive strategies to manage
CKD
According to the World Health Organization, preven-
tion of chronic diseases is of vital importance [155].
Many chronic diseases can be prevented since they are
caused by modifiable factors such as improper diet,
smoking or unsuitable lifestyles [156].
Chronic kidney disease is widely present in the world,
affecting around 10 % of the general population. In Italy
the prevalence of CKD is 6.3 % in the adult population
[157]. The number of patients starting dialysis programs
is constantly increasing and, therefore, during the course
of CKD it is mandatory to make the utmost effort to
postpone the initiation of dialysis as long as possible.
The majority of the measures required for this purpose
are organizational, aimed at reducing as much as pos-
sible the barriers that prevent effective treatment during
CKD, whether they involve medication, diet or lifestyle.
Delaying the initiation of dialysis treatment also means
significant savings for the health system [158]. To be
sure, it has been proven that the deferral of one to two
years of dialysis results in savings of around 30–50,000
euros per patient [159]. Therefore it is crucial to administer
suitable treatments, as well as to organize services able to
offer the best treatment programs to CKD patients not in
dialysis. It is not enough to solely provide knowledge of the
remedies for the most severe risk factors, since even after
very serious episodes of the disease, the correction of
mistaken patient habits is very limited [160]. One of the
causes of this behaviour is the patient’s difficulty in under-
standing what the physician is telling him, yet at the same
time lacking the courage to ask for clarification. At times, it
is the physician who does not wish to, or is unable to,
Table 2 Criteria suggested for the nutritional monitoring of patients with CKD in conservative treatment. Most nutritional variables
should be obtained every 3 months
Category Nutritional variable Additionally useful variables
Biochemical markers Albumin < 3,8 g/dL
Total cholesterol < 100 mg/dL
Transferrin, prealbumin
Inflammatory markers: CRP, Total lymphocyte
count or percentage
Body mass BMI < 23 Kg/m2
Unintentional weight-loss > 5 % in 3 months
or > 10 % in 6 months
Reduced fat mass < 10 %
Bioelectrical Impedance Analysis
Muscle mass Reduction of muscle mass by 5 % in 3 months
or 10 % in 6 months
Reduced AMA by 10 % as compared to the
50th percentile of the reference population
DEXA (6 months interval)
CT and/or MRI (6 months interval)
Measurements of muscle strength and function
(for example handgrip, 6 min walking test)
Nutritional intake Unintentional DPI < 0.6 g/kg/day for at
least 2 months
Unintentional DEI < 25 kcal/kg/day for
at least 2 months
Appetite assessment questionnaires
Food frequency and dietary recall questionnaires
Measuring energy expenditure by indirect calorimetry
Protein catabolic rate (PCR)
Nutritional scoring system Subjective Global Assessment (SGA)
Malnutrition-inflammation Score (MIS)
AMA arm muscle area, BMI body mass index, CRP C-reactive protein, CT computed tomography, DEI dietary energy intake, DEXA dual energy X-ray absorptiometry,
DPI dietary protein intake, MRI magnetic resonance
Bellizzi et al. BMC Nephrology  (2016) 17:77 Page 12 of 17
explain more clearly and in more detail. As a result, the
patient may not follow the recommendations, or may do so
only in part [161, 162].
The belief emerging around the world is that only an
active and aware patient will decide to follow both
suggested advice and treatment, according to a “chronic
care model” [163]. The Italian Society of Nephrology has
developed a CKD program which leans in this direction
[164]. The program describes in detail all the efforts and
procedures which medical staff should make in order to
inform, educate and support the patient in his/her goal
towards understanding the disease and the therapy. A
recent ministerial decree regarding the management of
CKD contains chapters regarding therapeutic education
as fundamental and essential issues in the treatment of a
patient with kidney disease.
There is now a need to set up a program involving
multidisciplinary and coordinated action among phy-
sicians, nursing staff, dietitians, physiotherapists and
psychologists, to be preceded by periodical meetings in
which the entire team acquires the necessary expertise
and establishes coordination between the various mem-
bers of the team. Informative materials are also required
for the users (brochures, manuals, videos, cd’s, etc.).
Since the majority of patients are elderly and many of
them prefer television viewing over reading, educational
videos could encourage and motivate patients to suitably
follow the recommendations provided. It is also essential
to define when the patient should be called for educa-
tional and training meetings, as well as which member(s)
of the team should preside at each consultation, whether
the physician together with the dietitian, or the physician
with the nurse. When dietary information is provided,
the caregiver who prepares the daily meals (next of kin,
care-worker or other individual) must be present. The
available materials must be viewed together with a
medical professional. Generally the healthcare assistant
or nurse has greater affinity with the patient, to whom
the patient can refer in order to clarify any doubts which
may have arisen during the patient-doctor consultation.
Therefore, the patient will be motivated to clarify and
gain better understanding of the program that is being
illustrated. If videos are available, access can be granted
to the patient by sharing via DVD, USB sticks or
YouTube links.
A periodical internal audit to evaluate the results of
the strategies used and, if necessary, to modify them, is
fundamental in guaranteeing the success of the entire
program.
Summary
Italian nephrologists have a longstanding tradition in
implementing low protein diets in the treatment of CKD
patients, with the aim of alleviating uremic symptoms
through reducing the toxins derived from excessive-
intake of unnecessary protein [1]. Another aim was to
improve the nutritional aspects of the CKD patients by
providing adequate energy intake with protein of high
biological value, eventually supplemented with essential
aminoacids or their ketoanalogs. A not excluded aim
was the possibility of slowing down the progression of
CKD or at least to delay the need for dialysis. The
current issue of the journal is a clear demonstration of
this expertise. Moreover, the current issue is also a
strong demonstration of the renewed interest of Italian
nephrologists in revisiting this established field, with the
aim of not only reducing the protein intake of CKD
patients but also of implementing a wider and more
correct nutritional therapy [8]. The major aspects of this
novel approach were to pay more careful attention to
energy intake and to the quality of proteins, achieved by
the use of new protein-free foods of greatly improved
quality, and also by paying attention to phosphate and
sodium intakes. The low-protein diet program is now
much more ambitious with the goal of improving the
nutritional aspect of a population that is increasing in
age, by carefully considering the amount and quality of
protein intake, mainly the phosphate content and the
amount of salt in the diet. The Idea was to reduce the
progression of renal insufficiency through the reduction
of proteinuria, through a better control of blood pres-
sure values, and by the correction of metabolic acidosis.
However, the experiences here reported clearly demon-
strate the different dietary approaches in the various
centres resulting from a well-recognised Italian flexibility
and innovativeness in the field, both in treating non
dialysis CKD patients, and in using low-protein diets as
a bridge between conservative treatment and the start of
chronic three-times a week dialysis therapy as an incre-
mental dialysis approach. The main goal of this flexible
approach is to favour patient compliance, which is a
crucial factor in the successful implementation of a low-
protein diet program.
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